Sensus Healthcare Reports Q4/FY25 Loss, Projects 2026 Profitability Driven by 300% Reimbursement Increase
SRTS sits 44% above its 52-week low of $3.03.
Summary
Sensus Healthcare reported significant losses for Q4 and full-year 2025, but provided optimistic 2026 guidance, expecting full-year profitability driven by a 300% increase in CMS reimbursement for its SRT technology.
Key Events · Earnings and Guidance · SRTS
-
Q4 & FY 2025 Financial Performance
Sensus Healthcare reported a net loss of $3.2 million for Q4 2025 and $7.7 million for the full year 2025, a significant decline from net income in the prior year, with revenues also decreasing substantially.
-
New CMS Reimbursement Codes
Dedicated CPT codes for SRT to treat non-melanoma skin cancer, effective January 1, 2026, include a 300% per-fraction increase to the delivery code, providing significant reimbursement certainty.
-
2026 Outlook and Profitability Target
Management expects sequential-quarter revenue growth in Q1 2026 and aims for full-year profitability, leveraging the enhanced reimbursement and a diversified customer base.
-
SRT System Shipments
The company shipped 14 SRT systems in Q4 2025, an increase from Q3, notably without any contribution from its historically largest customer, indicating successful customer diversification.
Analysis · SRTS · Industrial Applications And Services
Sensus Healthcare's latest 8-K reveals a challenging 2025 with substantial revenue declines and a shift to net losses for both the fourth quarter and the full year. However, the filing's market-moving importance stems from the highly positive forward guidance for 2026. The company highlights the new CMS Physician Fee Schedule Final Rule, which provides a significant 300% per-fraction increase to the delivery code for its Superficial Radiotherapy (SRT) technology, effective January 1, 2026. This reimbursement certainty, coupled with management's expectation of sequential revenue growth in Q1 and a target for full-year profitability in 2026, signals a potential turnaround. Investors will likely focus on the impact of these new reimbursement rates and the company's ability to execute on its profitability objective, especially given its stable cash position and efforts to diversify its customer base.
At the time of this filing, SRTS was trading at $4.35 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $76.4M. The 52-week trading range was $3.03 to $5.92. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.